The global Stem Cell Therapy market size was exhibited at USD 12.9 billion in 2022 and is projected to hit around USD 46.74 billion by 2032, growing at a CAGR of 13.74% during the forecast period 2023 to 2032.
Key Takeaways:
Stem Cell Therapy Market Report Scope
Report Coverage |
Details |
Market Size in 2023 |
USD 14.67 Billion |
Market Size by 2032 |
USD 46.74 Billion |
Growth Rate From 2023 to 2032 |
CAGR of 13.74% |
Base Year |
2022 |
Forecast Period |
2023 to 2032 |
Segments Covered |
Product, Therapy Type, Application, Technology, End User, Geography |
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key Companies Profiled |
Caladrius, CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank, Opexa Therapeutics, Inc., Pluristem Therapeutics Inc, STEMCELL Technologies Inc., Biovault family, Precious Cells International, Ltd, Mesoblast Ltd, Seneca Biopharmaceuticals, Inc. |
Stem Cell Therapy Market Dynamics
Drivers: Availability of funding for stem cell research
Stem cell research funding has strengthened in the past few years, attributed to the need for novel therapeutic interventions in patients with cardiovascular, neurological, and autoimmune disorders. The NIH funding for stem cell research reached its highest peak in 2018 and has shown a year-on-year growth of more than 5% in the stem cell research funding each year. This trend is expected to continue with the increase in funding initiatives announced in 2021. For instance, in September 2021, the California Institute for Regenerative Medicine granted a grant of USD 31 million to Stanford Research for launching first-in-human trials of stem cells in the treatment of heart failure, stroke, and spinal cord tumours.
Restraints: Ethical concerns related to embryonic stem cells
Studies exploring the therapeutic potential of embryonic stem cells (ESC) are associated with various ethical issues attributed to the destruction of human embryos. Lack of proper federal policies that define what can be funded in embryo-based stem cell research or therapy development may restrain the market's expansion in the future to a certain extent. In addition, the complexities of regulations in this area require federal guidelines that can support researchers, scientists, and pharmaceutical companies to develop ESC therapy and further facilitate its commercialization.
Type Insights
Depending upon the type, the allogeneic stem cell therapy segment accounted for about 59.5% in the 2022. As the allergenic stem cell segment has seen a growing demand in the past which is due to the usage in treatment against cancer and the growing number of cases of this dreadful disease will create a greater demand in the coming years. With the help of the immune system cells the cancerous cells can be killed and these cells can be acquired from a donor. The segment is expected to grow well in the coming years due to its increased application for treating different types of cancers like leukemia lymphoma and myeloma.
Apart from the growing demand for to allogeneic segment the autologous segment is also expected to grow well in the coming years the autologous therapy segment is expected to grow at a higher compound annual growth rate in the coming years. As the use of this therapy reduces the chances of complications the market is expected to grow well. Also, the use of this therapy is expected to grow well in the coming years due to the lower chances of the rejection of the graft. The use of this treatment has largely affected the market as the survival rates have increased. This segment is expected to grow well in the coming years as it is affordable as compared to the other type. This happens to be a low-risk alternative.
Application Insights
Depending upon the basis of application, the region relative medicine segment is expected to have the largest share in the market in the coming years. The segment has dominated the market in the past with a share of about 92% and it is expected to grow well in the coming years. The demand for regenerative medicine especially for the neurological disorders is expected to grow in the coming years as that has been an increased number of approvals that are associated with the clinical trials for treating different types of diseases. Governments of various nations are increasing their investments for developing the regenerative medicines. These medicines will be helpful in treating different chronic disorders, diabetes, heart disease and blood disorder.
Apart from the growing demand of the stem cell therapy or the stem cells market for various regenerative medicines they shall be good demand for the development and the discovery of the drugs.
End User Insights
On the basis of the end user, the hospital segment is expected to have a dominant position in the coming years. The way level infrastructure and the different types of treatment options will help in the growth of the market in the coming years. As the hospitals have been instrumental in providing good treatment to the patience due to their association with the various research institutes which help them in coming up with novel therapies against various diseases these collaborations have being extremely favorable for the growth of the market in the past and they shall be instrumental in developing the market in the future.
Regional Insights
The North American region has dominated the market in the past and it is expected to have a dominant position even in the coming years. This region had a share of about 53% in the past as major manufacturing units are present in the North American region. The availability of the research and development units and advanced infrastructure in the healthcare segment shall be instrumental in the growth of the market. Constant reforms in this nation that are supportive for the healthcare sector and the presence of favorable reimbursement policies will play a great role in the growth of the market. Initiatives taken by the government in the United States are highly favorable for the research activities.
Constant promotion and awareness regarding the use of this therapies for various diseases through these organizations will be instrumental in increasing the demand for the treatment. The Asia Pacific region is also expected to grow well in the coming years and it is expected to grow at the highest compound annual growth rate of about 9.2% in the coming years. Favorable initiatives from the government and increased research activities will be helpful in the development of the stem cell treatments market in the Asia Pacific region.
Some of the prominent players in the Stem Cell Therapy Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Stem Cell Therapy market.
By Product
By Therapy Type
By Application
By Technology
By End User
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Stem Cell Therapy Market
5.1. COVID-19 Landscape: Stem Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Stem Cell Therapy Market, By Product
8.1. Stem Cell Therapy Market, by Product, 2023-2032
8.1.1. Adult Stem Cells (ASCs)
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Human Embryonic Stem Cells (HESCs)
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Induced Pluripotent Stem Cells (iPSCs)
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Very Small Embryonic Like Stem Cells
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Stem Cell Therapy Market, By Therapy Type
9.1. Stem Cell Therapy Market, by Therapy Type, 2023-2032
9.1.1. Autologous
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Allergenic
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Stem Cell Therapy Market, By Application
10.1. Stem Cell Therapy Market, by Application, 2023-2032
10.1.1. Regenerative Medicine
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Drug Discovery and Development
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Stem Cell Therapy Market, By Technology
11.1. Stem Cell Therapy Market, by Technology, 2023-2032
11.1.1. Cell Acquiition
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cell Production
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Cryopreservation
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Expansion and Sub-Culture
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Stem Cell Therapy Market, By End User
12.1. Stem Cell Therapy Market, by End User, 2023-2032
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Research institutes
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. surgical institutes
12.1.3.1. Market Revenue and Forecast (2020-2032)
12.1.4. Orders
12.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Stem Cell Therapy Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.1.3. Market Revenue and Forecast, by Application (2020-2032)
13.1.4. Market Revenue and Forecast, by Technology (2020-2032)
13.1.5. Market Revenue and Forecast, by End User (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Technology (2020-2032)
13.1.6.5. Market Revenue and Forecast, by End User (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Application (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Technology (2020-2032)
13.1.7.5. Market Revenue and Forecast, by End User (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.2.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.4. Market Revenue and Forecast, by Technology (2020-2032)
13.2.5. Market Revenue and Forecast, by End User (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.6.4. Market Revenue and Forecast, by Technology (2020-2032)
13.2.6.5. Market Revenue and Forecast, by End User (2020-2032)
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.7.4. Market Revenue and Forecast, by Technology (2020-2032)
13.2.7.5. Market Revenue and Forecast, by End User (2020-2032)
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.8.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.8.4. Market Revenue and Forecast, by Technology (2020-2032)
13.2.8.5. Market Revenue and Forecast, by End User (2020-2032)
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Application (2020-2032)
13.2.9.4. Market Revenue and Forecast, by Technology (2020-2032)
13.2.9.5. Market Revenue and Forecast, by End User (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.3.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.4. Market Revenue and Forecast, by Technology (2020-2032)
13.3.5. Market Revenue and Forecast, by End User (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Technology (2020-2032)
13.3.6.5. Market Revenue and Forecast, by End User (2020-2032)
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.7.4. Market Revenue and Forecast, by Technology (2020-2032)
13.3.7.5. Market Revenue and Forecast, by End User (2020-2032)
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Technology (2020-2032)
13.3.8.5. Market Revenue and Forecast, by End User (2020-2032)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.9.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.3.9.3. Market Revenue and Forecast, by Application (2020-2032)
13.3.9.4. Market Revenue and Forecast, by Technology (2020-2032)
13.3.9.5. Market Revenue and Forecast, by End User (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.4.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.4. Market Revenue and Forecast, by Technology (2020-2032)
13.4.5. Market Revenue and Forecast, by End User (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Technology (2020-2032)
13.4.6.5. Market Revenue and Forecast, by End User (2020-2032)
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.7.4. Market Revenue and Forecast, by Technology (2020-2032)
13.4.7.5. Market Revenue and Forecast, by End User (2020-2032)
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Technology (2020-2032)
13.4.8.5. Market Revenue and Forecast, by End User (2020-2032)
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.9.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.4.9.3. Market Revenue and Forecast, by Application (2020-2032)
13.4.9.4. Market Revenue and Forecast, by Technology (2020-2032)
13.4.9.5. Market Revenue and Forecast, by End User (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.5.3. Market Revenue and Forecast, by Application (2020-2032)
13.5.4. Market Revenue and Forecast, by Technology (2020-2032)
13.5.5. Market Revenue and Forecast, by End User (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Technology (2020-2032)
13.5.6.5. Market Revenue and Forecast, by End User (2020-2032)
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.7.2. Market Revenue and Forecast, by Therapy Type (2020-2032)
13.5.7.3. Market Revenue and Forecast, by Application (2020-2032)
13.5.7.4. Market Revenue and Forecast, by Technology (2020-2032)
13.5.7.5. Market Revenue and Forecast, by End User (2020-2032)
Chapter 14. Company Profiles
14.1. Caladrius
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. CELGENE CORPORATION
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. ReNeuron Group plc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Virgin Health Bank
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Opexa Therapeutics, Inc
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Pluristem Therapeutics Inc
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. STEMCELL Technologies Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Biovault family
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Precious Cells International Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Mesoblast Ltd
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms